IL-13Rα2 Peptide Vaccine for Glioma via Dendritic Cell Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for brain cancer, such as surgery, radiotherapy, and chemotherapy, are ineffective due to the invasive growth patterns and the blood-brain barrier, leading to a need for alternative therapies like immunotherapy, particularly for malignant gliomas, where few cytotoxic T lymphocyte epitopes have been identified, and existing peptide-based vaccines face challenges in inducing specific CTL responses and expansion.
Innovation Solution
Development of IL-13Rα2 peptide-based vaccines, including substitutions and combinations with other brain cancer-associated peptides like EphA2, YKL-40, GP100, survivin, and WT1, administered with helper T cell epitopes and immune response modifiers, to induce cytotoxic T lymphocyte responses and enhance immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (surgery, radiotherapy, chemotherapy) are used for brain cancer, then treatment delivery is straightforward, but treatment effectiveness is poor due to invasive growth patterns and blood-brain barrier
Solution Approach 1:
The patent uses dendritic cells as intermediary carriers to deliver tumor-specific peptides across the blood-brain barrier. The dendritic cells act as mediators that can navigate the biological barriers and present antigens directly to T cells within the tumor microenvironment, thereby improving treatment effectiveness without requiring complex external delivery systems
Solution Approach 2:
The patent employs the patient's own immune system and autologous dendritic cells to fight the tumor. By using the body's natural immune mechanisms and self-generated cellular carriers, the treatment achieves effectiveness through biological self-service rather than external mechanical intervention
2Measurement precision
If peptide-based vaccines are used to target specific tumor antigens, then antigen-specificity is improved, but the ability to induce strong CTL responses is insufficient
Solution Approach 1:
The patent combines multiple tumor-specific peptides (IL-13Rα2, EphA2, YKL-40, GP100, survivin, WT1) with dendritic cell vaccination and adjuvant therapy into an integrated immunotherapy approach. This merging of multiple antigen-specific components enhances both the specificity and the strength of the CTL response beyond what single peptides could achieve
Solution Approach 2:
The vaccine formulation uses a composite approach by loading dendritic cells with multiple peptide antigens and combining them with adjuvants. This composite structure allows simultaneous presentation of multiple tumor-associated antigens, generating robust and specific CTL responses against various glioma markers
3Adaptability or versatility
If multiple tumor-associated peptides are combined in the vaccine, then broad tumor coverage is improved, but vaccine complexity increases
Solution Approach 1:
The dendritic cell platform serves as a universal carrier that can accommodate and present multiple different peptide antigens simultaneously. This multi-functional approach allows a single vaccine formulation to target multiple glioma-associated antigens (IL-13Rα2, EphA2, YKL-40, GP100, survivin, WT1), providing broad tumor coverage without requiring separate vaccines for each antigen
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant.